Skip to main content

What the FDA labels say about taking them together

Rifampin and rolapitant

Rolapitant's FDA label of August 19, 2020 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name rolapitant. The rolapitant label: “Co-administration of VARUBI with rifampin can significantly reduce the plasma concentrations of rolapitant and decrease the efficacy of VARUBI.”

Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the rolapitant FDA label on DailyMed (effective August 19, 2020, TerSera Therapeutics LLC).

What does the rifampin label say about rolapitant?

Rifampin's label (effective February 11, 2026) does not name rolapitant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

What does the rolapitant label say about rifampin?

Rolapitant label, drug interactions

Clinical Impact: Co-administration of VARUBI with rifampin can significantly reduce the plasma concentrations of rolapitant and decrease the efficacy of VARUBI. Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers.

Source: FDA drug label (Varubi), TerSera Therapeutics LLC, effective August 19, 2020 (SPL set a52896cd-4a98-49b8-82db-bf1985a64d97), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

13Rifampin generic labelers
0Rolapitant generic labelers
RifampinRolapitant
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.679 per capsule 300 mg capsulen/a
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?